Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 8/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.48 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.47 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.47 |
| ▸ | PIM1 | P11309 | 4/20 | 0.47 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4206795 | 1.00 | HPGD (0.50) | HPGDAKR1B1CISD1GPR35PIM1 | |
| SCHEMBL4206790 | 1.00 | HPGD (0.50) | HPGDAKR1B1CISD1GPR35PIM1 | |
| Hydrochloric Acid SCHEMBL3967725 | 0.99 | HPGD (0.49) | HPGDAKR1B1CISD1GPR35PIM1 | |
| Hydrochloric Acid SCHEMBL3967722 | 0.99 | HPGD (0.49) | HPGDAKR1B1CISD1GPR35PIM1 | |
| SCHEMBL3967342 | 0.90 | HPGD (0.53) | HPGDAKR1B1CISD1GPR35PIM1 | |
| SCHEMBL3967333 | 0.90 | HPGD (0.53) | HPGDAKR1B1CISD1GPR35PIM1 | |
| SCHEMBL6245391 | 0.88 | PPARG (0.45) | HPGDAKR1B1CISD1GPR35PIM1 | |
| SCHEMBL13868974 | 0.88 | HPGD (0.47) | HPGDAKR1B1CISD1GPR35PIM1 | |
| SCHEMBL3964115 | 0.88 | HPGD (0.47) | HPGDAKR1B1CISD1GPR35PIM1 | |
| SCHEMBL13875922 | 0.87 | HPGD (0.53) | HPGDAKR1B1CISD1GPR35PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7521466-B2 | Dipeptide phenyl ethers | BEXEL PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-20070037863-A1 | such as 5-[4-(4-(2-(2-amino-3-imidazol-4-yl propanamido)-2-methoxy carobonylethyl)phenoxy)benzylidene]thiazolidin-2,4-dione, used for lowering blood glucose, serum insulin, free fatty acids, cholesterol and triglyceride levels; prophylaxis of diabetes, obesity, inflammation and autoimmune diseases | NAG BISHWAJIT | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037863-A1 | such as 5-[4-(4-(2-(2-amino-3-imidazol-4-yl propanamido)-2-methoxy carobonylethyl)phenoxy)benzylidene]thiazolidin-2,4-dione, used for lowering blood glucose, serum insulin, free fatty acids, cholesterol and triglyceride levels; prophylaxis of diabetes, obesity, inflammation and autoimmune diseases | FFAR4, IAPP, FFAR2 | HPGD 4199/4885AKR1B1 3293/4885CISD1 1506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.